Key Takeaways
- Major Funding Milestone: Tropic closed an oversubscribed $105 million Series C round led by Forbion and Corteva Catalyst.
- Commercial Expansion: Capital will be used to scale global production of the company’s banana and rice portfolios and accelerate climate-resilient crop pipelines.
- Proven Innovation: The funding follows the 2025 launch of the first new commercial banana varieties in 75 years, including non-browning and extended shelf-life traits.
- Disease Mitigation: Tropic is advancing a resistance program for Panama Disease (TR4), an existential threat to the $25 billion global banana industry.
- Supply Chain Impact: New varieties have demonstrated the ability to reduce transportation waste by up to 50% by extending “green life” by 12 days.
Tropic Accelerates Global Scale-Up of Gene-Edited Tropical Crops
Tropic, a biotechnology firm specializing in gene-edited tropical agriculture, has announced the successful closure of a $105 million Series C financing round. The investment aims to meet growing global demand for resilient food solutions by expanding the company’s large-scale plant production capabilities and strengthening international supply chains.
The financing round was co-led by Forbion, via its Bioeconomy Fund, and Corteva, through its Corteva Catalyst platform. Other participants included Just Climate, IQ Capital, and new investors ABN Amro and Invest International, alongside several existing shareholders.
Advancing Disease Resistance and Shelf-Life Innovation
The investment follows a year of significant milestones for Tropic, notably the commercial introduction of a non-browning banana and a variety with an extended shelf life. The extended shelf-life variety lengthens the fruit's green life by 12 days, which facilitates new export routes and significantly reduces waste during transit.
